NCT04706598 2024-07-12Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG TreatmentFudan UniversityPhase 1/2 Active not recruiting25 enrolled
NCT05564897 2022-10-04Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder CancerZhejiang Cancer HospitalPhase 2 Unknown25 enrolled